Streamlining Cancer Diagnostic Tests for Effective Immunotherapy at AstraZeneca
5 May 2016
Dr Marianne Ratcliffe of Personalised Healthcare and Biomarkers at AstraZeneca, discusses research that demonstrates the interchangeability of PD-L1 assays and how these diagnostics can be better used to select effective immunotherapies for cancer patients.
